Professor Jérôme Frenette is a researcher with a background in physical therapy and post-graduate training in muscle physiology and immunology at the University of California in Los-Angeles. He is a full-time researcher at the Centre de recherche du CHU de Québec-Laval University, and full professor in the department of rehabilitation at Laval University’s School of Medicine. He has been the principal investigator on several CIHR and NSERC grants. Many of his publications, and one CIHR grant were recognized and rewarded as being among the best in the field of muscle physiology. He started his career as a researcher by investigating the roles played by blood cells and mechanical loading in models of tendon injury and muscle atrophy/regrowth. In 2005, he expanded his research program to include the Buruli Ulcer, which is caused by mycobacterium ulcerans, a neglected disease of wet tropical zones, that is closely related to tuberculosis and leprosy. His research group was the first to show that mycobacterium ulcerans and its toxin, mycolactone, extend well beyond the skin, and severely affect underlying skeletal muscles. Today, the focus of his research program is to understand the link between osteoporosis and muscle atrophy/disease through one common pathway i.e. the RANK/RANKL/OPG pathway. In collaboration with Duchenne muscular dystrophy foundations in Canada, the United States and Australia, as well as sustainable financial support from public and private sources, his team is developing new drugs that would potentially alleviate, in tandem, osteoporosis and muscle degeneration in Duchenne muscular dystrophy patients or other forms of bone and muscle diseases.
2705, boulevard Laurier
P-09800
Québec, Québec
Canada G1V 4G2
Latest news
- Un projet mené par Sachiko Sato soutenu par la fondation Jesse’s Journey 2021-05-25
- Quatorze chercheurs du CRCHU reçoivent près de 9 millions de dollars de subvention des IRSC 2020-02-28
- Un sucre contre la dystrophie musculaire – Un supplément alimentaire dérivé du glucose produit des effets spectaculaires chez des souris atteintes de dystrophie musculaire de Duchenne 2018-06-28
- Argaw, AntenehEmployeeCHUL+1 418-525-4444, extension 48840Anteneh.Argaw@crchudequebec.ulaval.ca
2705, boulevard Laurier
P-09800
Québec, Québec
Canada G1V 4G2 - Bouredji, ZinebDoctoral studentCHUL+1 418-525-4444, extension 47954zineb.bouredji.1@ulaval.cazineb.bouredji@crchudequebec.ulaval.ca
2705, boul. Laurier
P-09800
Québec, Québec
Canada G1V 4G2
In vivo expression of intercellular adhesion molecule 1 in type II pneumocytes during hyperoxia
Journal ArticleAm J Respir Cell Mol Biol, 15 (1), 1996.
Effect of carbonic anhydrase III inhibition on substrate utilization and fatigue in rat soleus
Journal ArticleCan J Physiol Pharmacol, 71 (3-4), 1993.
Fatigue and recovery of rat soleus muscle are influenced by inhibition of an intracellular carbonic anhydrase isoform
Journal ArticleAm J Physiol, 260 (3 Pt 2), 1991.
Active projects
- Decipher the physiological functions of osteoprotegerin in skeletal and cardiac muscles, from 2023-04-01 to 2028-03-31
- Development of a monosaccharide therapy using N-acetylglucosamine to mitigate Duchenne muscular dystrophy, from 2021-05-31 to 2024-05-30
- Multifunctional properties of osteoprotegerin in muscular dystrophy and muscle repair, from 2020-04-01 to 2025-03-31
Recently finished projects
- Deciphering the role of RANK/RANKL/OPG in skeletal muscle., from 2016-04-01 to 2022-03-31
- Development of a glycobiology therapy to mitigate the progression of Duchenne muscular dystrophy, from 2021-07-01 to 2023-02-28
- Does anti-RANKL therapy prevent glucocorticoid induced bone loss and promote muscle function in a mouse model of Duchenne muscular dystrophy, from 2021-04-01 to 2022-03-31
- Does anti-RANKL therapy prevent glucocorticoid induced bone loss in a mouse model of Duchenne muscular dystrophy?, from 2020-10-01 to 2021-07-31
- Investigation of the role of galectin-3 and its ligands in skeletal muscle strength, regeneration, and pathology, from 2018-10-01 to 2023-03-31
- La protéine S100B est-elle un outil de dépistage valide pour réduire le nombre de tomodensitométries inutiles suite à un traumatisme cranio-cérébral léger?, from 2017-04-01 to 2022-01-31